X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson’s Disease Therapy
Gainesville, United States, June 23rd, 2026, FinanceWire
X-tosis Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Novel Parkinson’s Disease Therapy. The ward supports advancement of X-tosis’s mitochondrial approach and accelerates development of its lead Parkinson’s candidate toward the clinic.
X-tosis, Inc., a precision-medicine biotechnology company founded in 2024 and dedicated to developing novel mitochondrial therapeutics for neurodegenerative diseases, today announced it has been awarded a $2.74 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Parkinson’s Disease Therapeutics Pipeline Program. The funding will support advancement of XTS001, the lead candidate from the company’s MitoXTS platform, a paten...